Antitussive effect of WIN 55212-2, a cannabinoid receptor agonist

European Journal of Pharmacology

Volumn 474, Issue 2-3, 2003, Pages 269-272

  Morita, Kayo ^a   Kamei, Junzo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Antitussive effect; Cannabinoid CB1 receptor; Cough; SR141716A; WIN 55212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; BETA FUNALTREXAMINE; BINALTORPHIMINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; KAPPA OPIATE RECEPTOR; METHYSERGIDE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; NALOXONAZINE; NALOXONE; OPIATE ANTAGONIST; OPIATE RECEPTOR; RIMONABANT; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0142038856     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)02009-0     Document Type: Article

References (14)

1. Compton D.R., Gold L.H., Ward S.J., Balster R.L., Martin B.R. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 263:1992;1118-1126.
2. Fan F., Compton D.R., Ward S., Melvin L., Martin B.R. Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J. Pharmacol. Exp. Ther. 271:1994;1383-1390.
3. Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L., James I. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 92:2001;91-100.
4. Kamei J., Ogawa M., Kasuya Y. Monoamines and the mechanisms of action of antitussive drugs in rats. Arch. Int. Pharmacodyn. Ther. 290:1987;117-127.
5. Kamei J., Ogawa M., Kasuya Y. Supersensitivity of 5, 7- dihydroxytryptamine-treated rats to the respiratory depressant and antitussive effects of dihydrocodeine. Eur. J. Pharmacol. 153:1988;305-308.
6. 2-mediated mechanisms in μ-mediated antitussive activity in the mouse. Neurosci. Lett. 149:1993;169-172.
7. 1-opioid receptor-deficient CXBK mice. Eur. J. Pharmacol. 240:1993;99-101.
8. Martin B.R. Identification of the endogenous cannabinoid system through integrative pharmacological approaches. J. Pharmacol. Exp. Ther. 301:2002;790-796.
9. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johnson M.R., Melvin L.S., Mechoulam R., Ward S.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 140:1991;471-478.
10. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (Lond.). 346:1990;561-564.
11. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature (Lond.). 365:1993;61-66.
12. 9-tetrahydrocannabinol and morphine in the spinal cord. J. Pharmacol. Exp. Ther. 279:1996;608-616.
13. 9-tetrahydrocannabinol and kappa opioids in mice. J. Pharmacol. Exp. Ther. 268:1994;1382-1387.
14. Welch S.P. Modulation of cannabinoid-induced antinociception by nor-binaltorphimine but not ICI 174,864 in mice. J. Pharmacol. Exp. Ther. 265:1993;633-640.